Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Corp. (Lexaria Bioscience Corp.) on June 18, 2013. The report discloses the unregistered sale of equity securities in the form of stock options granted to directors, officers, and a consultant under the company's 2010 Stock Option Plan.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on the terms of a specific equity grant.
Material Changes and Equity Grant Details
On June 18, 2013, the company granted a total of 500,000 stock options. The key terms of this grant are:
- Exercise Price: US$0.10 per share
- Vesting Schedule: Immediate vesting
- Expiration Date: June 18, 2018
The options were allocated as follows:
| Recipient | Options Granted |
|---|---|
| Chris Bunka | 225,000 |
| Bal Bhullar | 175,000 |
| David DeMartini | 50,000 |
| Barbara Farr | 50,000 |
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors related to the company's operations. Item 7.01 references a press release regarding an appointment, but the text of that release is not included in this summary.
Investor Verification Checklist
- Verify the total number of outstanding options and shares authorized under the 2010 Stock Option Plan to assess dilution impact.
- Confirm the current market price of Lexaria stock relative to the $0.10 exercise price to evaluate the intrinsic value of the grant.
- Review the referenced Exhibit 99.1 (Press Release) for details on the appointment mentioned in Item 7.01.
- Check subsequent filings for any changes to the vesting schedule or expiration dates.